NCT02768805 - Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults | Biotech Hunter

Enrollment

900

Participants

Timeline

Start Date

March 2, 2016

Primary Completion Date

May 17, 2016

Study Completion Date

November 26, 2016

Conditions

Virus DiseasesRNA Virus InfectionsRespiratory Tract DiseasesRespiratory Tract Infections

Interventions

BIOLOGICAL

15 µg/strain of Quadrivalent VLP Vaccine

Single dose of non-adjuvanted Quadrivalent VLP Vaccine

BIOLOGICAL

30 µg/strain of Quadrivalent VLP Vaccine

Single dose of non-adjuvanted Quadrivalent VLP Vaccine

BIOLOGICAL

15 µg/strain of the licensed quadrivalent vaccine

Single dose of the licensed quadrivalent vaccine

Trial Locations (9)

Regional Clinical Research (RCR), Endwell

Broward Research Group (BRG), Hollywood

Miami Research Associates (MRA), South Miami

Topstone Research, Toronto

Diex Research Montreal, Montreal

McGill University Health Center - Vaccine Study Center (MUHC), Pierrefonds

Diex Research Sherbroooke, Sherbrooke

Équipe de recherche en vaccination du CHU de Québec-Université Laval (CHU), Québec

Centre de Recherche St-Louis, Québec